Index

Note: Page numbers in italics refer to figures; page numbers in bold refer to tables
Abbreviations
  cGVHD – chronic graft-versus-host disease
  GVHD – graft-versus-host disease
  HSCT – hematopoietic stem cell transplantation

A
  abdominal pain 281, 283
  activities, posttransplant 335–336
  acute graft-versus-host disease gastrointestinal see gastrointestinal graft-versus-host disease
  hepatic see hepatic graft-versus-host disease acute infections gastrointestinal 280–281
  late-onset, allogenic-HSCT recipients 23
  see also infections
  acute infections, gastrointestinal 280–281
  acute myeloid leukemia treatment-related (t-AML) 35, 66, 67
  see also leukemia; myeloid malignancies
  acyclovir, prevention of cytomegalovirus infection 107
  adefovir therapy, hepatitis B virus infection 296
  adenovirus infections 108–109
  adjustment, psychosocial see psychosocial adjustment issues
  adult height, effects of HSCT 204
  adults
  health-related quality of life 345–360
  global 347
  interventions 356, 359
  physical function 347–348
  posttrauma growth 351–352
  psychological function 348
  social and role functioning 350
  survivors of childhood cancer, transition from pediatric care 13–14
  adverse health outcomes, caregivers 341–342
  after-cataract 165
  age, as risk factor for secondary malignancy 69
  alcohol-based hand gels 132
  aldosterone antagonists, hypertension management 273, 273
  alendronate 318
  alkylation agents
    gonadal effects
      females 194–195
      males 183, 184, 196
    interactions with antiretroviral medications 301
  see also specific alkylation agents
  allied health professionals 17, 17–18, 52–54
  allogenic hematopoietic stem cell transplantation
    follow-up 333
    HIV-infected patients 300, 301
    indications 8, 8, 9
    late effects 4–5, 21–28
    common nonrelapse late effects 22, 23–27
    dynamics of etiology 21, 22
    future directions 28
    identification 22–23
    very late effects 22, 27–28
  see also chronic graft-versus-host disease (cGVHD); specific complications
  posttransplant routines and guidelines 332–339, 339
  sun exposure following 336–337
  transplant data and trends 8, 8, 9, 9
  amantadine 121, 133
  ambulatory blood pressure monitoring 270–271
  American Society of Blood and Marrow Transplantation, bronchiolitis obliterans syndrome screening recommendations 143
  angiotensin-converting enzyme inhibitors (ACEIs) 273, 273
  angiotensin receptor blockers (ARBs) 273, 273
  anorexia 174–175, 176
  animal models, chronic graft-versus-host disease 88
  anorexia 282–283
  antifungal prophylaxis
    Aspergillus infection 109–110
    Candida infection 109
    antigen detection tests, influenza diagnosis 120
    antihypertensive drugs 253, 272–273
    antineoplastic therapies, previous, as risk factor for secondary malignancy 69
    antioxidant supplementation 328
    antiretroviral therapy 296–297
    hepatitis C virus infection 298–299
    influenza 120–121
    Aspergillus infection 107, 108
    hepatitis B virus infection 295
    herpes simplex virus infection 108
    influenza 133
    varicella zoster virus infection 108, 134–135
    antiviral prophylaxis
    cytomegalovirus infection 107, 108
    hepatitis B virus infection 295
    herpes simplex virus infection 108
    influenza 133
    varicella zoster virus infection 108, 134–135
    antiviral treatment
    hepatitis B virus infection 296, 296–297
    hepatitis C virus infection 298–299, 299
    influenza 120–121
    Aspergillus infection 107, 109–110
    asplenia, functional, susceptibility to bacterial infections 106
    assisted reproduction techniques 185
    outcomes 198–199
    atherosclerosis 46, 248, 249, 250
    autoimmune, in chronic graft-versus-host disease 78, 88, 89, 90–91
    autoimmune thyroiditis 228–229
    autologous cell mobilization method, as risk factor for secondary malignancy 70


Index
diarrhea 278–281, 282–283
case gastrointestinal graft-versus-host disease 278–279, 279
chronic gastrointestinal graft-versus-host disease 282, 282
infection-associated 280
medication-induced 281
diet, neutropenic 338
dietary modifications
diabetes management 219
hyperlipidemia management 253, 263
hypertension management 253, 272
dietary sources
calcium 153, 154
vitamin D 155
dietary supplementation see supplement use
dipeptidyl peptidase-4 (DPP-4) 220

dietary modifi cations
diet, neutropenic 338

drug-related complications
end-stage renal disease (ESRD) 304
treatment 309–310
see also chronic kidney disease (CKD), post-HSCT
treatment, effect on cardiovascular risk 262
see also specifi c complications
endoscopy, acute gastrointestinal graft-versus-host disease 279, 279
endothelial injury, role in cardiovascular disease pathogenesis 46, 248–249, 250
end-stage renal disease (ESRD) 304
treatment 309–310
see also chronic kidney disease (CKD), post-HSCT
entecavir therapy, hepatitis B virus (HBV) infection 296, 297
cosinophilic fasciitis 93
epithelial growth plate (EGP) 203–204
Epstein–Barr virus (EBV) infection 107, 108
management 72, 73, 108
posttransplant lymphoproliferative disorder association 47, 66, 67, 71, 108
viral load monitoring 71–72, 108
erythematous candidiasis 174
esophagus
chronic graft-versus-host disease 25, 281–282
infections 282
secondary malignancy 282
etanercept 318
eosinophilic fasciitis 93
etoricoxib, cutaneous chronic graft-versus-host disease 99
exercise 335–336
fall prevention 153
extracorporeal photopheresis (ECP)
chronic graft-versus-host disease 144
steroid-refractory cGVHD 97–98, 98
eye
anatomy 163
complications see ocular complications
erythema, dry eye syndrome/ocular graft-versus-host disease management 168
eye shielding, during total body irradiation 165

dyschromia see hyperlipidemia, post-HSCT
dysmotility 278, 281–282

eating out, precautions 338–339
education
caregiver see caregiver education
patient see patient education
embryo cryopreservation 199–200
endemic infections, allogenic-HSCT recipients 23
endocrine complications
late
allogenic HSCT 25
autologous HSCT 33–35
recommendations for screening and prevention 62

E
fall prevention 153
family members
caregivers see caregiver(s)
relationship issues 369–370
role in prevention of infectious complications 334–335

F
female fertility
post-HSCT 193–196, 238–239
effects of chemoradiotherapy 194–195, 238–239
management of fertility issues 195–196
preservation and counseling 199, 199–200
see also pregnancy, post-HSCT
female genital tract graft-versus-host disease 25, 233–236
clinical evaluation 234–235
differential diagnosis 235
incidence and risk factors 233–234
severity scoring 234, 234

treatment and prevention 235–236
female gonadal function, chemoradiotherapy effects 194–195, 238–239
female HSCT recipients 233–240
care and screening recommendations 237
fertility see female fertility, post-HSCT
genital GVHD see female genital tract graft-versus-host disease
gonadal failure see ovarian failure
gonadal function, chemoradiotherapy effects 194–195, 238–239
HPV infection see human papillomavirus (HPV) infection
return to work 372
fenofibrate 264, 265
fertility, post-HSCT
allogenic-HSCT recipients 26
autologous-HSCT recipients 34
female see female fertility, post-HSCT
male see male fertility, post-HSCT
preservation and counseling 199, 199–200, 239
see also infertility

fibric acid derivatives 264, 265
fibrogenic cytokines, role in chronic graft-versus-host disease 44, 88, 89, 89–90
fibrovascular polyp, oral 173
fine-needle aspiration biopsy (FNAB), thyroid nodule 230
fludarabine
cardiotoxicity 245
gastrointestinal effects 277, 277
Fludase (DAS181) 121, 123–124
Index}

follicle-stimulating hormone (FSH)
hepatitis B virus (HBV) infection 109, 290–291, 294–297
diagnosis 290, 290–291
epidemiology 294
management 291, 296, 296–297
patients with active infection 291, 296, 296–297
patients with indeterminate infection 297
patients with resolved infection 297
post-HSCT complications 293–296
pre-transplant evaluation 290, 290, 295
prevention 295
reverse seroconversion 290, 295–296
prevention 295
hepatitis C virus (HCV) infection 109, 291, 297–299
hepatitis C virus (HCV) 297
hepatocellular carcinoma (HCC) 109, 298
hepatitis B virus (HBV) infection 109, 392
histopathology
hip fracture 151
human immunodeficiency virus infection 297
human bocavirus (HBoV) 124
human papillomavirus (HPV)
human parainfluenza virus (HPV1) 116, 123–124, 131
human rhinovirus (HRHV) 124
Hurler syndrome 204
3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors see statins
hypercholesterolemia
mechanisms 259
prevalence and incidence 258–259
see also hyperlipidemia, post-HSCT
hyperferritinemia 291, 328
hyperleptinemia 249
hyperlipidemia, post-HSCT 248, 251, 258–266
diabetes and 221–222
follow-up 266
management 251, 253, 260–265, 261, 264
Adult Treatment Panel III
guidelines 253, 262
pharmacologic therapy 253, 263–265, 264
mechanisms 259–260
prevalence and incidence 258–259
screening and evaluation 251, 252, 260, 261
hyperprolactinemia 187
hypertension
definition 269
post-HSCT 248, 251, 269–274
diabetes and 221–222, 269–270
incidence and prevalence 269–270
long-term implications 271–272
risk factors 270
screening 251, 252, 270–271, 271
treatment 251, 253, 272–273
workup 271, 271
see also cardiovascular disease, post-HSCT
hypothyroidism 226, 228–229
causes 228–229
evaluation and treatment 229
risks 228
signs and symptoms 228
subclinical 35
hypertriglyceridemia
prevalence and incidence 258, 259
see also hyperlipidemia, post-HSCT
hypogammaglobulinemia 132, 315
hypoglycemia, diabetes management and 220
hypoglycemic agents, oral 219–220, 221
hypogonadism
allogeneic-HSCT recipients 25–26
autologous-HSCT recipients 34
metabolic syndrome and 249
see also male hypogonadism; ovarian failure
hypomagnesemia 249, 328–329
hypothyroidism 25, 35, 226, 226–228, 249
cardiovascular risk and 249, 252
evaluation 227–228
management 227–228, 252
pregnancy-related 226, 230
risks 227
signs and symptoms 227
subclinical 35, 225, 226
I
ibandronate 155
idiopathic pneumonia syndrome (IPS) 32
IGF-1 (insulin-like growth factor-1) 204–205
imatinib
antifibrotic effect 89–90, 90
cutaneous chronic graft-versus-host disease management 89–90, 90, 99, 99
immunizations see vaccinations
immunofluorescence, influenza diagnosis 120
immunosuppressive therapy 314–319
autologous HSCT 315–316
complications 316–319
neutropenia 259–260, 263
nephrotoxicity 305–306
oral 180
secondary malignancy 70–71
interactions
antiretroviral therapy 301
statin therapy 265–266
monitoring 314–319
autologous HSCT 315–316
general recommendations 314–315
need for long-term immunosuppressive agents 315
see also specific immunosuppressive agents
impaired glucose tolerance (IGT) 216, 218
infections
bacterial see bacterial infections
fungal see fungal infections
gastrointestinal see gastrointestinal infections
late-onset 106–110
allogeneic-HSCT recipients 23–24
recommendations for screening and prevention 59
oral 174–177, 278
community respiratory viral infections see community respiratory viral (CRV) infections
considerations in home environment 335
role of family and friends 334–335
risk factors and common pathogens 106, 107, 130
viral see viral infections
see also specific infections/pathogens
infectious esophagitis 282
infertility
allogeneic-HSCT recipients 25–26
autologous-HSCT recipients 34
female 193, 238–240
management 195–196
see also female fertility, post-HSCT
recommendations for screening and prevention 59

radiation therapy 245
cardiovascular complications 249, 250
effects on gonadal function 249, 250
chemoradiotherapy effects 120
real-time polymerase chain reaction (RT-PCR),
influenza diagnosis 120
rectal bleeding 281, 283
rectal pain 281, 283
reduced-intensity conditioning (RIC), late effects 167
relationship issues 369–370
relaxation techniques 373
renal complications 25, 251, 304–311
screening and prevention 61
see also chronic kidney disease (CKD), post-HSCT
renal function, assessment 307–308, 308
renal replacement therapy 309
resources, online see online patient resources
respiratory syncytial virus (RSV)
infections 116, 122–123, 131
management 123
prevention 122–123
respiratory viruses 107, 108, 131
see also community respiratory viral (CRV) infections
restrictive lung disease 45
retinopathy 164, 168–169
return to work 371–372
reverse seroconversion, hepatitis B 290, 295–296
rhinovirus, human (HRhV) 124
sirolimus therapy 317–318
sexually transmitted infections (STIs)
hepatitis C virus infection 298, 299, 299
respiratory syncytial virus infection 123, 132–133
risedronate 155
rituximab therapy 318
autologous HSCT 315–316
monitoring 318
posttransplant lymphoproliferative disorders 72, 73, 108
side effects 318
steroid-refractory chronic graft-versus-host disease 98, 98–99
role functioning, HSCT effects 350–351
rotavirus vaccine 134
routines, posttransplant 334
S
salivary gland complications 173, 177, 281
management 177, 178
sarcopenic obesity 205
sclerodermaform cutaneous cGVHD 91, 92, 93
see also cutaneous chronic graft-versus-host disease
sclerosis, cutaneous chronic graft-versus-host disease 79, 82, 85–86, 86–87, 87
sclerotic-type cutaneous chronic graft-versus-host disease (ScGVHD) 77–78, 78
manifestations at onset 78, 80–81
see also cutaneous chronic graft-versus-host disease
screening practices, guidelines 57–58, 59–63, 64, 379, 384
see also long-term follow-up, guidelines
screening questionnaires, nutrition 325
seasonal virus infections 116–124, 131
preventing disease 117
preventing exposure 116–117
see also specific infections
secondary malignancies 46–49, 65–73
allogeneic-HSCT recipients 27–28
autologous-HSCT recipients 35, 36–37
chronic graft-versus-host disease and 24, 27, 44, 48–49, 70–71
esophagus 282
incidence 68
models 65–68, 66
myeloid see myeloid malignancies
oral 173, 174, 179
PTLDs see posttransplant lymphoproliferative disorders (PTLDs)
risk factors 46–47, 68–71, 69
posttransplant 70–71
pretransplant 69–70
transplant factors 70
solid see solid malignancies
surveillance and prevention 71–72
recommendations 62
therapeutic strategies 72–73
self-examination, secondary malignancy
surveillance 71
semen analysis 185, 197
serologic testing, influenza diagnosis 120
severe combined immune deficiency (SCID),
effect of HSCT on neurocognitive functioning 209
sexual activity, posttransplant recommendations 336
sexual activity and function, HSCT effects
men 188–189, 190
women 190, 239–240
see also sexual dysfunction
sexual dysfunction
allogeneic-HSCT recipients 27
autologous-HSCT recipients 34
females 240
males 189
see also erectile dysfunction
recommendations for screening and prevention 63
see also hypogonadism
sexual relationships, intimacy issues 370–371
shingles vaccine 134
sildenafil 190, 191
sinusoidal obstruction syndrome 288–289
sirolimus therapy 317–318
chronic graft-versus-host disease 98, 99
Index

drug interactions 317
monitoring 317–318
side effects 317
dyslipidemia 260
Sjögren-like syndrome 166
skin cancer, post-HSCT 27, 48–49
skin chronic graft-versus-host disease see cutaneous chronic graft-versus-host disease
skin complications
allogenic HSCT 24
GVHD see cutaneous chronic graft-versus-host disease
see also specific complications
skin sclerosis score 94, 95
smallpox (vaccina) vaccine 135
social complications, allogenic-HSCT 27
social functioning, HSCT effects 350–351
socioeconomic status (SES), cognitive outcomes and 209, 220908
solid malignancies 47–49, 66, 68
allogenic-HSCT recipients 27
autologous-HSCT recipients 35, 36, 37
incidence 68
pathogenesis 47–48
see also secondary malignancies
steroid analysis 185, 197
steroid cryopreservation 185, 197, 200
fatherhood rates 198
spiritual issues 374
squamous cell carcinoma (SCC) 27, 48–49
oral 174, 179
statins 253, 263, 264
interaction with immunosuppressant agents 265–266
side effects 263, 265
stem cell sources 3–4, 9, 346
posttransplant recovery and 346
steroid-induced hyperglycemia 217
steroid-refractory chronic graft-versus-host disease, management 97–99, 98, 99
steroid therapy 316
bronchiolitis obliterans syndrome 144
cataract formation and 44, 165
chronic graft-versus-host disease 316
chronic graft-versus-host disease, cutaneous systemic 96–97
topical 94–95, 95
effect on insulin action 217, 217
female genital tract graft-versus-host disease 235
monitoring 316
organizing pneumonia 146
side effects 316
bone loss 151
dyslipidemia 259
stress, coping with 368–370
strictures, large intestinal 283
subacute non-suppurative cholangitis 289
subclinical hypothyroidism 35, 225, 226
Subjective Global Assessment (SGA) 325
sulfonylureas 219, 220, 221
sun exposure 336–337, 339
sunscreen application 336, 337
supplement use 325–329
antioxidants 328
calcium 327–328
herbal preparations 329
minerals 328–329
multivitamins 325–326
recommendations 329, 329
vitamin D 155, 156, 333–334, 339
support groups 369
patient’s perspective 376–378
surgical management, cataracts 165
survival guilt 373
survivors, long-term see long-term survivors
survivorship care plan 381–382
swimming 336
systemic sclerosis, cutaneous chronic graft-versus-host disease vs. 77, 78
T
tacrolimus 316
dyslipidemia association 260
role in posttransplant diabetes mellitus pathogenesis 217
steroid-refractory cGVHD management 98
tadalafil 190, 191
T cells
cardiac complications, late 245
cataract formation and 44, 162, 164, 165
cognitive outcomes and 209
eye shielding 165
fertility effects 194, 238
males 196
gastrointestinal effects 277, 277
as risk factor for posttransplant diabetes 216
as risk factor for secondary malignancy 70
total body irradiation (TBI) 27
thyroid disease 225–230, 226
allogenic-HSCT recipients 25
autologous-HSCT recipients 35
hyperthyroidism see hyperthyroidism
hypothyroidism see hypothyroidism
pregnancy and 226, 230
thyroidectomy 230
thyroid hormone replacement therapy 227, 228
thyroid nodules 225, 226, 229–230
thyroid stimulating hormone (TSH) levels 225
thyrotoxic periodic paralysis 228
Ticket to Work program 372
TNF (tumor necrosis factor) inhibitors 318
topical therapy
hypothyroidism 227
thyrotoxic periodic paralysis 228
treatment-related acute myeloid leukemia (t-AML) 35, 66, 67
treatment-related myelodysplastic syndrome (t-MDS) 35, 66, 67
tubular proteinuria 307, 308
tumor necrosis factor (TNF) inhibitors 318
type 2 diabetes 216
pathogenesis 12
lesions from cancer survivorship models 12–14
see also posttransplant diabetes mellitus (PTDM)
typhilitis 281
typhoid vaccine, oral 135
tyrosine kinase inhibitors, cutaneous chronic graft-versus-host disease management 99, 99

U
ultrasonography, thyroid 230

V
vaccinations
family members see family members
influenza see influenza vaccination
post-HSCT 53, 54, 333, 339
recommendations 110, 110
pre-transplant, hepatitis B 295
vaccina (smallpox) vaccine 135
vaccines
live 133–135
see also specific vaccines/vaccinations
vacuum-assisted erection devices 190
vaginal disease, genital graft-versus-host disease 234
vaginal scarring, management 234
vaginal–vulvar graft-versus-host disease see female genital tract graft-versus-host disease
valacyclovir, prevention of cytomegalovirus (CMV) infection 107
Vanderbilt transplant program 372
vardenafil 190, 191
varicella virus vaccines 134–135
varicella-zoster immune globulin, human 134–135
varicella zoster virus (VZV) infection 107, 108
vascular complications see cardiovascular disease, post-HSCT
veno-occlusive disease, hepatic 288–289
verruciform xanthoma 173–174
very late effects, allogenic HSCT 22, 27–28
see also specific complications
viral infections
hepatitis 290–291
see also hepatitis B virus (HBV) infection;
hepatitis C virus (HCV) infection
late-onset 106, 107, 107–109
allogenic-HSCT recipients 23
as risk factor for secondary malignancy 71
risk factors and common pathogens 106, 107
seasonal see seasonal virus infections
see also community respiratory viral (CRV) infections
viral isolation, influenza diagnosis 120
viral shedding 117, 131
influenza virus 117
visual imagery 373
vitamin D 154, 326
sources 155, 326
supplementation 155, 156, 326–327
vitamin D deficiency 154–156, 326–327
management 156, 326–327
monitoring 156
prevalence 156, 326
prevention 156
vitamin supplementation
prevalence 325–327
recommendations 329, 329
vomiting 278–281, 282–283
acute gastrointestinal graft-versus-host disease 278
chronic gastrointestinal graft-versus-host disease 282, 282
infection-associated 280
medication-induced 281, 283
post-chemotherapy 278
vulvar disease, genital graft-versus-host disease 234
W
walking, benefits 335–336
washing, hand 132, 333, 334, 338
weight changes 323–324
work, return to 371–372
Worldwide Bone Marrow Transplant Group (WBMT) 7
X
xerostomia 177, 281
Z
zanamivir 118–119, 121, 133
zinc deficiency 328
zoledronic acid 155
Z-scores 152, 205
pediatric HSCT recipients 204, 205, 206